Official publication of Rawalpindi Medical University
Visual Outcome of Intravitreal Bevacizumab in Treatment of Diabetic Retinopathy
PDF

How to Cite

1.
Kanwal Zareen Abbasi, Warda Ali, Qamar Farooq, Ali Raza, Ana Rizvi. Visual Outcome of Intravitreal Bevacizumab in Treatment of Diabetic Retinopathy. JRMC [Internet]. 2018 Mar. 30 [cited 2024 Mar. 29];22(1). Available from: https://journalrmc.com/index.php/JRMC/article/view/840

Abstract

Background :To evaluate the efficacy of monthly
intravitreal bevacizumab injections (1.25 mg/.05 ml)
in improving or stabilizing visual acuity measured
by Snellen’s visual acuity charts for diabetic
retinopathy.
Methods: This was a prospective Quasi
experimental study of 59 diabetic patients having
diabetic retinopathy with indication of intravitreal
anti VEGF,Bevacizumab. Patients diagnosed of
having fresh vitreous haemorrhage and diabetic
macular edema were included. Maximum three
intravitreal bevacizumab injections were given, each
with a dose of 1.25mg in 0.05ml(at 0month, 1 month,
2 months) with final follow up at the period of 3
months. The criteria for improvement was a gain of
at least one line on Snellen’s visual acuity chart,
compared to the baseline while stabilization was
considered if the visual acuity was unchanged
relative to the baseline.
Results: A total of 59 patients, 25 (49.1%) males and
34 (50.84%) females , having age range 40-65
years,were given intravitreal injection. Twenty six
eyes (44.06%) with diabetic macular edema showed
improvement while visual acuity was stabilized in 4
eyes (6.7%). In patient with vitreous hemorrhage, 27
eyes (45.76%) showed improvement while
stabilization of visual acuity was noted in 2 eyes
(3.3%). No patient with worsening of visual acuity
was noted.
Conclusion: Intravitreal Bevacizumab is very
effective in improving the visual outcome in diabetic
patients having macular edema and vitreous
hemorrhage

PDF